Meroponia (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, disrupting peptidoglycan cross‑linking, which leads to cell lysis and death. Its structure confers stability against many β‑lactamases, providing activity against a wide range of Gram‑positive, Gram‑negative and anaerobic organisms.

The dose of Meroponia is determined by the prescribing clinician based on infection type, severity, renal function and patient weight. Dosing regimens are individualized and should follow local antimicrobial stewardship guidelines and the product’s prescribing information.

Safety data for meropenem in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only when the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To request Meroponia, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Meroponia (meropenem) shares the carbapenem class’s broad‑spectrum activity and β‑lactamase stability, but it has a slightly lower affinity for certain Pseudomonas strains compared with imipenem‑cilastatin. It is not co‑administered with a renal dehydropeptidase inhibitor, which can simplify dosing and reduce nephrotoxicity risk.

Meroponia should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vials in the original packaging to maintain sterility and stability until preparation for intravenous administration.

Meroponia is supplied as an injectable solution for intravenous infusion. It is reconstituted with the appropriate diluent, filtered if required, and administered over a prescribed period, typically 15‑30 minutes, under aseptic conditions by qualified healthcare personnel.

Serious adverse reactions to Meroponia include hypersensitivity (anaphylaxis), seizures, Clostridioides difficile‑associated colitis, severe renal impairment, thrombocytopenia and neutropenia. Patients should be monitored for these events, especially those with pre‑existing CNS disorders or renal dysfunction.

Meroponia is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving interacting medications such as valproic acid.